Douleur et Analgésie

, Volume 14, Issue 4, pp 177–180 | Cite as


  • Fr. Cesselin


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ashton C.H.: Pharmacology and effects of cannabis: a brief review.Br. J. Psychiat. 178, 101–106, 2001.CrossRefGoogle Scholar
  2. 2.
    Benson M. andBentley A.M.: Lung disease induced by drug addiction.Thorax 50, 1125–1127, 1995.PubMedCrossRefGoogle Scholar
  3. 3.
    Breivogel C.S., Griffin G., Di Marzo V. andMartin B.R.: Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.Mol. Pharmacol. 60, 155–163, 2001.PubMedGoogle Scholar
  4. 4.
    Brenneisen R., Egli A., Elsholy M.A., Henn V. andSpiess Y.: The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients.Int. J. Clin. Pharmacol. Ther. 34, 446–452, 1996.PubMedGoogle Scholar
  5. 5.
    Campbell F.A., Tramèr M.R., Carroll D., Reynolds D.J.M., Moore R.A. andMcQuay H.J.: Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review.BMJ 323, 13–16, 2001.PubMedCrossRefGoogle Scholar
  6. 6.
    Consroe P., Musty R., Rein J., Tillery W. andPertwee R.: The perceived effects of smoked cannabis on patients with multiple sclerosis.Eur. J. Neurol. 38, 44–48, 1997.Google Scholar
  7. 7.
    Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S. andHowlett A.C.: Determination and characterization of a cannabinoid receptor in rat brain.Mol. Pharmacol. 34, 605–613, 1988.PubMedGoogle Scholar
  8. 8.
    Di Marzo V., Bisogno T., De Petrocellis L., Brandi I., Jefferson R.G., Winckler R.L., Davis J.B., Dasse O., Mahadevan A., Razdan R.K. andMartin B.R.: Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor «hybrid» ligands.Biochem. Biophys. Res. Commun. 281, 444–451, 2001.PubMedCrossRefGoogle Scholar
  9. 9.
    Dyer O.: Cannabis trial launched in patients with MS.BMJ 322, 192, 2001.CrossRefGoogle Scholar
  10. 10.
    Finnegan-Ling D. andMusty R.E.: Marinol and phantom limb pain: a case study.Proc. Int. Cannabinoid Res. Soc., 53, 1994.Google Scholar
  11. 11.
    Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L. andJames I.: The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.Pain 92, 91–100, 2001.PubMedCrossRefGoogle Scholar
  12. 12.
    Gaoni Y. andMechoulam R.: Isolation, structure, and partial synthesis of an active constituent of hashish.J. Am. Chem. Soc. 86, 1646–1647, 1964.CrossRefGoogle Scholar
  13. 13.
    Holdcroft A., Smith M., Jacklin A., Hogson H., Smith B., Newton M. andEvans F.: Pain relief with oral cannabinoids in familial Mediterannean fever.Anaesthesia 52, 483–486, 1997.PubMedCrossRefGoogle Scholar
  14. 14.
    Jain A.K., Ryan J.R., McMahon F.G. andSmith G.: Evaluation of intramuscular levonantradol and placebo in acute postoperative pain.J. Clin. Pharmacol. 21 (Suppl. 8–9), 320S-326S, 1981.PubMedGoogle Scholar
  15. 15.
    Jarai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., Zimmer A.M., Bonner T.I., Buckley N.E., Mezey E., Razdan R.K., Zimmer A. andKunos G.: Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.Proc. Natl. Acad. Sci. USA 96, 15136–14141, 1999.CrossRefGoogle Scholar
  16. 16.
    Malan T.P., Ibrahim M.M., Deng H., Liu Q., Mata H.P., Vanderah T., Porreca F. andMahriyannis A.: CB2 cannabinoid receptor-mediated peripheral antinociception.Pain 93, 239–245, 2001.PubMedCrossRefGoogle Scholar
  17. 17.
    Martyn C.N., Illis L.S. andThom J.: Nabilone in the treatment of multiple sclerosis.Lancet 345, 579, 1995.PubMedCrossRefGoogle Scholar
  18. 18.
    Maurer M., Henn V., Dittrich A. andHofmann A.: Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial.Eur. Arch. Psychiatry Clin. Neurosci. 240, 1–4, 1990.PubMedCrossRefGoogle Scholar
  19. 19.
    Mechoulam R.: The pharmacohistory ofCannabis sativa. In Mechoulam R (Ed), Cannabinoids as Therapeutic Agents, CRC Press, 1986, pp. 1–19.Google Scholar
  20. 20.
    Noyes R., Brunk S.F., Avery D.A. andCanter A.C.: The analgesic properties of delta-9-tetrahydrocannabinol and codeine.Clin. Pharmacol. Ther. 18, 84–89, 1975.PubMedGoogle Scholar
  21. 21.
    Noyes R., Brunk S.F., Baram D.A. andCanter A.: Analgesic effect of delta-9-tetrahydrocannabinol.J. Clin. Pharmacol. 15, 139–143, 1975.PubMedGoogle Scholar
  22. 22.
    Pertwee R.G.: Prescribing cannabinoids for multiple sclerosis-current issues.CNS Drugs 11, 327–334, 1999.CrossRefGoogle Scholar
  23. 23.
    Pertwee R.G.: Cannabinoid receptors and pain.Prog. Neurobiol. 63, 569–611, 2001.PubMedCrossRefGoogle Scholar
  24. 24.
    Robson P.: Therapeutic aspects of cannabis and cannabinoids.Br. J. Psychiat. 178, 107–115, 2001.CrossRefGoogle Scholar
  25. 25.
    Staquet M., Gantt C. andMachin D.: Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain.Clin. Pharmacol. Ther. 23, 397–401, 1978.PubMedGoogle Scholar
  26. 26.
    Tognetto M., Amadesi S., Harrison S., Creminon C., Trevisani M., Carreras M., Matera M., Geppetti P. andBianchi A.: Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation.J. Neurosci. 21, 1104–1109, 2001.PubMedGoogle Scholar
  27. 27.
    Tramèr M.R., Carroll D., Campbell F.A., Reynolds D.J.M., Moore R.A. andMcQuay H.J.: Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.BMJ 323, 16–21, 2001.PubMedCrossRefGoogle Scholar
  28. 28.
    Williamson E.M. andEvans F.J.: Cannabinoids in clinical practice.Drugs 60, 1303–1314, 2000.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2001

Authors and Affiliations

  • Fr. Cesselin

There are no affiliations available

Personalised recommendations